Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABT-165 + Paclitaxel |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABT-165 | Dilpacimab|ABT 165|ABT165 | DLL4 Antibody 7 VEGF Antibody 15 | Dilpacimab (ABT-165) is a bispecific antibody that binds to and inhibits signaling of both DLL4 and VEGF, which potentially results in tumor growth inhibition (PMID: 29592882). | |
| Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01946074 | Phase I | ABT-165 ABT-165 + Budigalimab + Paclitaxel ABT-165 + Budigalimab ABT-165 + Paclitaxel ABT-165 + Fluorouracil + Irinotecan + Leucovorin | A Study of ABT-165 in Subjects With Solid Tumors | Completed | USA | 0 |